Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

A Critical Evaluation of Inflammatory Markers in Huntington’s Disease Plasma

Författare

Summary, in English

BACKGROUND: Huntington’s Disease (HD) is a hereditary, progressive neurodegenerative disorder characterised by both neurological and systemic symptoms. In HD, immune changes can be observed before the onset of overt clinical features raising the possibility that immune markers in plasma could be used to track disease progression. It has previously been demonstrated that a widespread, progressive innate immune response is detectable in plasma throughout the course of HD.

OBJECTIVE: The aim of the present study was to investigate the potential of several components of innate immunity as plasma biomarkers in HD.

METHODS: We utilised antibody-based detection technologies as well as mass spectrometric quantification, multiple reaction monitoring (MRM-MS).

RESULTS: Levels of several markers previously described as altered in HD, such as clusterin, complement component 4, complement component 9 and α-2 macroglobulin did not differ between healthy controls and HD subjects as measured by Luminex, ELISA or MRM-MS. C-reactive protein was decreased in early HD, while the other immune markers tested were unaltered.

CONCLUSIONS: Of the immune markers tested in this study, none showed potential to track with HD disease progression.

Publiceringsår

2013

Språk

Engelska

Sidor

125-134

Publikation/Tidskrift/Serie

Journal of Huntington's disease

Volym

2

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

IOS Press

Ämne

  • Neurology

Status

Published

Forskningsgrupp

  • Biomarkers in Brain Disease

ISBN/ISSN/Övrigt

  • ISSN: 1879-6397